- Home
- CAG vs PCVX Comparison
CAG vs PCVX Comparison
Compare CAG & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAG | PCVX |
|---|---|---|
| Founded | 1919 | 2013 |
| Country | United States | United States |
| Employees | 26100 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.0B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CAG | PCVX |
|---|---|---|
| Price | $13.15 | $56.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 11 |
| Target Price | $14.38 | ★ $109.00 |
| AVG Volume (30 Days) | ★ 8.2M | 1.2M |
| Earning Date | 09-30-2026 | 11-03-2026 |
| Dividend Yield | ★ 5.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,500,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.53 | $39.87 |
| 52 Week High | $20.32 | $65.00 |
Technical Indicators
Market Signals| Indicator | CAG | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 21.33 | 44.39 |
| Support Level | $12.67 | $52.18 |
| Resistance Level | $14.55 | $58.77 |
| Average True Range (ATR) | 0.38 | 2.19 |
| MACD | -0.18 | -0.27 |
| Stochastic Oscillator | 4.69 | 30.24 |
Price Performance
Historical ComparisonAbout CAG ConAgra Brands Inc.
Conagra Brands Inc is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). The majority of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company sells through the USA retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.